HEPA — Hepion Pharmaceuticals Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -219.34% | ||
| Return on Equity | -378.4% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hepion Pharmaceuticals, Inc. is a biotechnology company developing a portfolio of diagnostic and therapeutic candidates for serious liver, immune, and inflammatory diseases. Through its subsidiary Gravitas Life Sciences, LLC, a clinical-stage biotechnology company, it is advancing therapeutic candidates in immunology and inflammation, including a transmucosal buccal film of an established opioid antagonist and an oral formulation of a validated anti-inflammatory antibody. Its diagnostic program is built on circulating tumor RNA technology, which reads actively expressed tumor transcripts for the early detection of hepatocellular carcinoma in high-risk cirrhotic patients, a cancer that is curable when found early. Its two licensed programs include GV104 and GV023. GV104 is a transmucosal buccal film of an approved opioid antagonist in clinical development for the temporary prophylaxis of respiratory and/or central nervous system depression. GV023 is an oral formulation of infliximab.
Directors
- Gary Jacob NEC (74)
- Robert Foster CEO (62)
- John Cavan CFO (62)
- Todd Hobbs OTH
- Timothy Block IND (66)
- John Brancaccio IND (73)
- Arnold Lippa IND (74)
- Petrus Wijngaard IND (58)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- May 15th, 2013
- Public Since
- February 7th, 2014
- No. of Shareholders
- 659
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 123,220,317
- Address
- 399 Thornall St, EDISON, 08837-2236
- Web
- https://hepionpharma.com/
- Phone
- +1 3026587581
- Auditors
- Grassi & Co., CPAs, P.C.
Latest News for HEPA
Upcoming Events for HEPA
Q3 2026 Hepion Pharmaceuticals Inc Earnings Release
Q4 2026 Hepion Pharmaceuticals Inc Earnings Release
Similar to HEPA
ABPRO Holdings
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adaptin Bio
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
FAQ
As of Today at 21:06 UTC, shares in Hepion Pharmaceuticals are trading at $0.14. This share price information is delayed by 15 minutes.
Shares in Hepion Pharmaceuticals last closed at $0.14 and the price had moved by +105.41% over the past 365 days. In terms of relative price strength the Hepion Pharmaceuticals share price has outperformed the S&P500 Index by +83.89% over the past year.
The overall consensus recommendation for Hepion Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreHepion Pharmaceuticals does not currently pay a dividend.
Hepion Pharmaceuticals does not currently pay a dividend.
Hepion Pharmaceuticals does not currently pay a dividend.
To buy shares in Hepion Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.14, shares in Hepion Pharmaceuticals had a market capitalisation of $17.25m.
Here are the trading details for Hepion Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: HEPA
Based on an overall assessment of its quality, value and momentum Hepion Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Hepion Pharmaceuticals is $30.00. That is 21328.57% above the last closing price of $0.14.
Analysts covering Hepion Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$6.45 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hepion Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +228.92%.
As of the last closing price of $0.14, shares in Hepion Pharmaceuticals were trading +117.65% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Hepion Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Hepion Pharmaceuticals' management team is headed by:
- Gary Jacob - NEC
- Robert Foster - CEO
- John Cavan - CFO
- Todd Hobbs - OTH
- Timothy Block - IND
- John Brancaccio - IND
- Arnold Lippa - IND
- Petrus Wijngaard - IND